Rapt Therapeutics Inc (RAPT) - News Archive

Showing 8 of 8 results.

RAPT Therapeutics to Announce Phase 2 Trial Results for RPT904 in Chronic Spontaneous Urticaria

RAPT Therapeutics, Inc., a clinical-stage biopharmaceutical company based in South San Francisco, is poised to release topline data from its Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneou...

Oct 20, 2025 • Major Pharmaceutical Preparations Industry Clinical Study

RAPT Therapeutics and Shanghai Jemincare Forge Strategic Alliance for Novel Anti-IgE Antibody, Expanding Global Reach

In a promising development within the biopharmaceutical arena, RAPT Therapeutics, a pioneering player focusing on transformative therapies for autoimmune diseases and cancer, has announced an exclusive license agreement...

Dec 27, 2024 • Major Pharmaceutical Preparations Industry Partnership Therapeutics Third Quarter Inc Therapeutics Therap

Turning the Tide RAPT Therapeutics Revamps Focus Amid Clinical Hurdles, Advances Next-Gen Therapies,

A Pivotal Turn for RAPT Therapeutics: Navigating Clinical Setbacks, Advancing Research Horizons SOUTH SAN FRANCISCO, Calif. In light of recent developments, RAPT Therapeutics, Inc. a clinical-stage biopharmaceutical com...

Nov 11, 2024 • Major Pharmaceutical Preparations Industry Clinical Study Pharmaceuticals So Therapeutics Therapeutics Inc S

Current Challenges and Potential Strategies for RAPT Therapeutics Inc A Detailed Analysis

In recent times, the shares of RAPT Therapeutics Inc (NASDAQ: RAPT) have experienced considerable frustration for investors. This article aims to provide an overview and interpretation of relevant articles to shed light...

Jun 25, 2024 • Major Pharmaceutical Preparations Industry Stocks on the Move Therapeutics Inc U After Therapeutics Inc Therapeu

In a groundbreaking development, RAPT Therapeutics has announced highly promising results from its phase 2 trial involving Tivumecirnon in combination with anti-PD-1 immunotherapy. The study focused on patients with head and neck cancer who had prior experience with CPI (checkpoint inhibitors) treatments. The findings have unveiled a significant breakthrough in the treatment of this challenging ...

Revealing Tivumecirnon s Potential: Groundbreaking Phase 2 Trial Demonstrates Impressive Response Rate in CPI-Experienced Head and Neck Cancer Patients, Regardless of PD-L1 or HPV StatusIn a groundbreaking development,...

Apr 9, 2024 • Major Pharmaceutical Preparations Industry Clinical Study

RAPT Therapeutics Faces Investor Investigation for Potential Securities Law Violations

As reported on March 11, 2024, prominent stockholder rights law firm Bragar Eagel & Squire, P.C. announced its investigation into RAPT Therapeutics, Inc. (NASDAQ: RAPT) on behalf of the company s stockholders. The law f...

Mar 12, 2024 • Major Pharmaceutical Preparations Industry Announcement RAPT Therapeutics

Light at the End of the Itch: RAPT Therapeutics' Zelnecirnon Shows Promising Results in Groundbreaking Clinical Trial for Atopic Dermatitis

RAPT Therapeutics Advances Treatment for Atopic Dermatitis with Promising Phase 1a/1b Clinical Trial of ZelnecirnonSOUTH SAN FRANCISCO, Calif., Nov. 27, 2023 - RAPT Therapeutics, a renowned clinical-stage biopharmaceuti...

Nov 27, 2023 Clinical Study

RAPT Therapeutics' FLX475 and Checkpoint Inhibitor Combo Shows Promise in Phase 2 Trial, Boosting Treatment Prospects for Advanced NSCLC Patients

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLCRAP...

Nov 3, 2023 Product Service News